POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.
Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manufacturing facility
POINT announced today they signed a research and clinical supply agreement with TerraPower for the medical radioisotope actinium-225 (Ac-225)
POINT Biopharma has entered into a definitive merger agreement with Research Alliance Corp. I (Nasdaq: RACA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “PNT”.